netFormulary NHS
Lancashire and South Cumbria
Formulary
 Search
 Formulary Chapter 2: Cardiovascular system - Full Section
 Useful Links
Link   Enoxaparin Shared Care Guideline **FOR USE IN THE MORECAMBE BAY REGION ONLY**
Link   Low Molecular Weight Heparins - Use in Primary care Best Practice Guideline *FOR USE IN PENNINE REGION ONLY*
Link   LSCMMG: Atrial Fibrillation
Link   LSCMMG: Heart Failure - Primary Care Guideline for the Use of SGLT-2 Inhibitors in Reduced Ejection Fraction Heart Failure
Link   LSCMMG: Lipid Management Pathway for Primary Prevention of Cardiovascular Disease
Link   LSCMMG: Lipid Management Pathway for Secondary Prevention of Cardiovascular Disease
Link   LSCMMG: Low Molecular Weight Heparins (LMWHs) Summary Prescribing Guide
Link   MHRA: Clopidogrel and proton pump inhibitors: interaction—updated advice
Link   NG 185 - Acute coronary syndromes
Link   NG 196 - Atrial fibrillation: diagnosis and management
Link   NICE NG106: Chronic heart failure in adults: diagnosis and management
Link   NICE NG136: Hypertension in adults: diagnosis and management
Link   NICE NG187: Acute heart failure: diagnosis and management
Link   NICE NG203: Chronic kidney disease: assessment and management
Link   NICE NG95: Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis
Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
02.01.01 Cardiac glycosides (2,0)
spacespace Digoxin-specific antibody (1,0)
02.01.02 Phosphodiesterase type-3 inhibitors (2,0)
02.02.01 Thiazides and related diuretics (3,0)
02.02.02 Loop diuretics (3,0)
02.02.03 Potassium-sparing diuretics and aldosterone antagonists (1,0)
spacespace Aldosterone antagonists (3,0)
02.02.04 Potassium-sparing diuretics with other diuretics (1,0)
02.02.05 Osmotic diuretics (1,0)
02.03.02 Drugs for arrhythmias (1,0)
spacespace Supraventricular arrhythmias (2,0)
spacespace Supraventricular and ventricular arrhythmias (6,0)
spacespace Ventricular arrhythmias (2,0)
02.04 Beta-adrenoceptor blocking drugs (12,0)
02.05.01 Vasodilator antihypertensive drugs (5,0)
02.05.02 Centrally acting antihypertensive drugs (3,0)
02.05.04 Alpha-adrenoceptor blocking drugs (1,0)
spacespace Phaeochromocytoma (2,0)
spacespace Heart Failure (2,0)
02.05.05.01 Angiotensin-converting enzyme inhibitors (ACE inhibitors) (4,0)
02.05.05.02 Angiotensin-II receptor antagonists (5,0)
02.05.05.03 Renin inhibitors (1,0)
02.06.01 Nitrates (3,0)
02.06.02 Calcium-channel blockers (9,0)
02.06.03 Other anitanginal drugs (4,0)
02.06.04 Peripheral vasodilators and related drugs (8,0)
02.07.01 Inotropic sympathomimetics (3,0)
02.07.02 Vasoconstrictor sympathomimetics (4,0)
02.07.03 Cardiopulmonary resuscitation (1,0)
02.08.01 Parenteral anticoagulants (1,0)
spacespace Heparin (1,0)
spacespace Low molecular weight heparins (3,0)
spacespace Heparinoids (1,0)
spacespace Heparin flushes (1,0)
spacespace Epoprostenol (1,0)
spacespace Fondaparinux (2,0)
02.08.02 Oral anticoagulants (9,0)
02.08.03 Protamine sulphate (1,0)
02.09 Antiplatelet drugs (6,0)
02.10.02 Fibrinolytic drugs (4,0)
02.11 Antifibrinolytic drugs and haemostatics (2,0)
spacespace Statins (5,0)
spacespace Bile acid sequestrants (2,0)
spacespace Ezetimibe (1,0)
spacespace Fibrates (2,0)
spacespace PCSK9 inhibitors (3,0)
spacespace Other lipid modifying agents (5,0)
02.13 Local sclerosants (1,0)
netFormulary